Loading patent…
AssigneesMitsubishi Pharma Corporation, Keio University
InventorsSaiko Hosokawa, Masahiko Aoki, Yoko Hirakawa, Seima Itami, Hiroe Umeki, Yoshiro Saikawa, Koichiro Kumai, Kazumasa Fukuda
Estimating the term…
A novel human monoclonal antibody specifically recognizing cancer cells such as non-small cell lung cancer, pancreatic cancer and gastric cancer cells is produced by hybridomas which are obtained by fusing lymphocytes derived from a cancer tissue of a cancer patient with mouse myeloma cells. An anti-cancer drug is obtained by using the antibody alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein. More specifically, an anti-cancer drug is obtained by using an antibody, in which variable region of its heavy chain comprises the amino acid sequence of SEQ ID NO: 115 and variable region of the light chain comprises the amino acid sequence of SEQ ID NO: 117, alone or anchoring the antibody on the surface of a liposome containing a toxin or an anti-cancer drug encapsulated therein.
An isolated monoclonal antibody which specifically binds human vimentin and which has a heavy chain and a light chain, wherein the variable region of the heavy chain of said the monoclonal antibody comprises the amino acid sequences of SEQ ID NOS:
Dependencies are inferred from the claim text.